Work

Immune-Related Adverse Events and Survival in Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma Treated with Immune Checkpoint Inhibitor–Based Therapy: A Landmark and Time-Dependent Analysis Accounting for Immortal Time Bias

Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Chemoimmunotherapy is the first-line standard for advanced gastric and gastro-oesophageal junction (G/GEJ) adenocarcinoma. Whether immune-related adverse events (irAEs) mark clinical benefit, and whether any signal survives correction for immortal time bias, remains uncertain, especially for individual organ systems. METHODS: We retrospectively studied 327 patients with advanced G/GEJ adenocarcinoma receiving immune checkpoint inhibitor (ICI)-based therapy; irAEs were graded by CTCAE v5.0. Associations with overall survival (OS) and progression-free survival (PFS) were assessed with a 12-week conditional landmark analysis, time-dependent Cox models treating irAE onset as a time-varying exposure, and a cumulative organ-burden model, adjusted for baseline covariates. Objective response rate (ORR) was compared by early (≤12-week) irAE status, with estimates examined across naive, landmark and time-dependent strategies. RESULTS: irAEs occurred in 152 patients (46.5%; grade 3-4, 8.6%), most often cutaneous (20.5%) and endocrine (14.4%). In the 12-week landmark, median OS was 35.8 versus 16.0 months and median PFS 19.0 versus 9.5 months (both log-rank P<0.001). The adjusted time-dependent HR was 0.44 (95% CI 0.31-0.61) for OS and 0.43 (0.32-0.58) for PFS. Each additional organ involved lowered the OS hazard (HR 0.52, 0.40-0.67). The benefit was organ-specific: cutaneous (HR 0.30) and endocrine (0.35) irAEs were protective, whereas hepatic, gastrointestinal, musculoskeletal and pulmonary events were not. Among landmark-eligible patients, ORR was higher with early irAEs (51.0% versus 35.4%, P=0.011). The naive estimate was the most extreme, attenuating only modestly after correction. CONCLUSIONS: irAEs - particularly cutaneous and endocrine events and those accumulating across organ systems - were independently associated with longer survival after correction for immortal time bias, supporting irAE onset as a dynamic on-treatment efficacy signal that warrants prospective validation.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7235883375
FWCI:
Cites: 27
Cited by:
Related to: 10